Palvella Therapeutics PVLA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's accounts payable?
- Palvella Therapeutics (PVLA) reported accounts payable of $851K in Q1 2026.
- How has Palvella Therapeutics's accounts payable changed year-over-year?
- Palvella Therapeutics's accounts payable decreased by 24.3% year-over-year, from $1.12M to $851K.
- What is the long-term trend for Palvella Therapeutics's accounts payable?
- Over 3 years (2021 to 2024), Palvella Therapeutics's accounts payable has grown at a -31.8% compound annual growth rate (CAGR), from $7.05M to $2.24M.